drugset / Trial / NCT01984138

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

NCT01984138

Phase 2 Active not recruiting 33 enrolled Polly A. Niravath, MD
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is investigating whether breast cancer patients who experience vaginal dryness while on anti-estrogen treatment could benefit from either vaginal estrogen or from a vaginal moisturizer called Replens.

Timeline

Start
2013-09
Primary completion
2025-06-03
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Estradiol Other / unclassified 7.5 ug Intrathecal
Subject Estradiol Other / unclassified 10 ug Intrathecal
Comparator Replens Unknown Intrathecal